Relationships between medicine and industry: Approaches to the problem of conflicts of interest

Annual Review of Medicine

Volumn 63, Issue , 2012, Pages 465-477

  Raad, Raymond ^a   Appelbaum, Paul S ^b  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b College of Physicians and Surgeons ^*  (United States)

Author keywords

disclosure; Medicalindustry relationships; Pharmaceutical industry; Principalagent problem; Professional ethics; Regulatory issues

Indexed keywords

BEHAVIOR; CLINICAL PRACTICE; CONFLICT OF INTEREST; DRUG INDUSTRY; FUNDING; GOVERNMENT; HUMAN; INTERPERSONAL COMMUNICATION; KNOWLEDGE; MEDICAL EDUCATION; MEDICAL RESEARCH; MEDICAL SCHOOL; MEDICAL STUDENT; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; PROFESSIONAL STANDARD; RESIDENT; REVIEW;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; CONFLICT OF INTEREST; DRUG INDUSTRY; EQUIPMENT SAFETY; HUMANS; PRIVATE PRACTICE; SCHOOLS, MEDICAL;

EID: 84855978026     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-061410-121850     Document Type: Review

References (65)

1. Institute of Medicine. 2009. Conflict of Interest in Medical Research, Education, and Practice. Washington, DC: Natl. Acad. Press
2. Nakayama DK. 2010. In defense of industry-physician relationships. Am. Surg. 76(9):987-94
3. Thompson DF. 1993. Understanding financial conflicts of interest. N. Engl. J. Med. 329(8):573-76 (Pubitemid 23232630)
4. Stolberg SG. 1999. The biotech death of Jesse Gelsinger. NY Times Mag., Nov. 28, pp. 136-40, 149-50
5. Assoc. Am. Med. Coll. 2008. Industry funding of medical education. http://www. ucsfcme. com/news/IndustryFundingMedicalEduation. pdf
6. Natl. Inst. Health. 2005. Summary of NIH-specific amendments to conflict of interest ethics regulations. http://www. nih. gov/about/ethics/summary- amendments-08252005. htm
7. U. S. Food Drug Admin. 2000. FDA guidance on conflicts of interest for advisory committeemembers, consultants, and experts. http://www. fda. gov/oc/advisory/conflictofinterest/guidance. html
8. Kowalczyk L. 2009. State bans drug firm gifts to doctors. Boston Globe, Mar. 12. http://www. boston. com/news/local/massachusetts/articles/2009/03/12/ state-bans-drug-firm-gifts-to-doctors/
9. Kaiser Family Found. 2010. Summary of new health reform law. Pub. No. 8061. http://www. kff. org/healthreform/upload/8061. pdf
10. Sierles FS, Brodkey AC, Cleary LM, et al. 2005. Medical students' exposure to and attitudes about drug company interactions: a national survey. JAMA 294(9):1034-42 (Pubitemid 41248444)
11. Zipkin DA, Steinman MA. 2005. Interactions between pharmaceutical representatives and doctors in training: a thematic review. J. Gen. Intern. Med. 20(8):777-86 (Pubitemid 41141015)
12. Reeder M, Dougherty J, White LJ. 1993. Pharmaceutical representatives and emergency medicine residents: a national survey. Ann. Emerg. Med. 22(10):1593-96 (Pubitemid 23296412)
13. Keim SM, Mays MZ, Grant D. 2004. Interactions between emergency medicine programs and the pharmaceutical industry. Acad. Emerg. Med. 11(1):19-26 (Pubitemid 38055782)
14. Sergeant MD, Hodgetts PG, Godwin M, et al. 1996. Interactions with the pharmaceutical industry: a survey of family medicine residents in Ontario. Can. Med. Assoc. J. 115(9):1243-48 (Pubitemid 26392085)
15. Steinman MA, Shlipak MG, McPhee SJ. 2001. Of principles and pens: attitudes and practices of medicine housestaff toward pharmaceutical industry promotions. Am. J. Med. 110(7):551-57
16. Holmer AF. 2001. Industry strongly supports continuing medical education. JAMA 285(15):2012-14 (Pubitemid 32366958)
17. Accreditation Council for Continuing Medical Education. 2009. 2009 annual report data. http://www. accme. org/index. cfm/fa/home. popular/popular-id/ 127a1c6f-462d-476b-a33a-6b67e131ef1a. cfm
18. Campbell EG, Gruen RL, Mountford J, et al. 2007. A national survey of physician-industry relationships. N. Engl. J. Med. 356(17):1742-50 (Pubitemid 46658706)
19. Steinman MA, Boscardin CK, Aguayo L, et al. 2010. Commercial influence and learner-perceived bias in continuing medical education. Acad. Med. 85(1):74-79
20. Ziegler MG, Lew P, Singer BC. 1995. The accuracy of drug information from pharmaceutical sales representatives. JAMA 273(16):1296-98
21. Spingarn RW, Berlin JA, Strom BL. 1996. When pharmaceutical manufacturers' employees present grand rounds, what do residents remember? Acad. Med. 71(1):86-88 (Pubitemid 26030842)
22. Bowman MA, Pearle DL. 1988. Changes in drug prescribing patterns related to commercial company funding of continuing medical education. J. Contin. Educ. Health Prof. 8(1):13-20
23. Gagnon MA, Lexchin J. 2008. The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States. PLoS Med. 5(1):e1
24. Anderson BL, Silverman GK, Loewenstein GF, et al. 2009. Factors associated with physicians' reliance on pharmaceutical sales representatives. Acad. Med. 84(8):994-1002
25. Kaiser Family Foundation. 2002. National survey of physicians part II: doctors and prescription drugs. http://www. kff. org/rxdrugs/loader. cfm?url=/commonspot/security/getfile. cfm&PageID=13965
26. Stryer D, Bero LA. 1996. Characteristics of materials distributed by drug companies: an evaluation of appropriateness. J. Gen. Intern. Med. 11(10):575-83 (Pubitemid 26403757)
27. Lexchin J. 1997. What information do physicians receive from pharmaceutical representatives? Can. Fam. Physician 43:941-45 (Pubitemid 127776791)
28. Wazana A. 2000. Physicians and the pharmaceutical industry: Is a gift ever just a gift?JAMA283(3):373-80 (Pubitemid 30051756)
29. Azoulay P. 2002. Do pharmaceutical sales respond to scientific evidence? J. Econ. Manage. Strategy 11(4):551-94
30. Narayanan S, Manchanda P, Chintagunta P. 2005. Temporal differences in the role of marketing communication for new products. J. Market. Res. 42(3):278-91
31. Boltri JM, Gordon ER, Vogel RL. 2002. Effect of antihypertensive samples on physician prescribing patterns. Fam. Med. 34(10):729-31 (Pubitemid 35340407)
32. Chew LD, O'Young TS, Hazlet TK, et al. 2000. A physician survey of the effect of drug sample availability on physicians' behavior. J. Gen. Intern. Med. 15(7):478-83 (Pubitemid 30640259)
33. Dorsey ER, de Roulet J, Thompson JP, et al. 2010. Funding of US biomedical research, 2003-2008. JAMA 303(2):137-43
34. Zinner DE, Campbell EG. 2009. Life-science research within US academic medical centers. JAMA 302(9):969-76
35. Blumenthal D, Campbell EG, Causino N, et al. 1996. Participation of life-science faculty in research relationships with industry. N. Engl. J. Med. 335(23):1734-39 (Pubitemid 26399349)
36. Bekelman JE, Li Y, Gross CP. 2003. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 289(4):454-65 (Pubitemid 36119966)
37. Perlis RH, Perlis CS, Wu Y, et al. 2005. Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry. Am. J. Psychiatry 162(10):1957-60 (Pubitemid 41428627)
38. Schott G, Pachl H, Limbach U, et al. 2010. The financing of drug trials by pharmaceutical companies and its consequences. Part 1. Dtsch. Arztebl. Int. 107(16):279-85
39. Lexchin J. 2011. Those who have the gold make the evidence: how the pharmaceutical industry biases the outcomes of clinical trials of medications. Sci. Eng. Ethics Epub ahead of print. http://www. springerlink. com/content/k3306qh046375277/
40. Jorgensen AW, Hilden J, Gotzsche PC. 2006. Cochrane reviews compared with industry supportedmetaanalyses and other meta-analyses of the same drugs: systematic review. BMJ 333(7572):782-85 (Pubitemid 44583357)
41. Yank V, Rennie D, Bero LA. 2007. Financial ties and concordance between results and conclusions in meta-analyses: retrospective cohort study. BMJ 335(7631):1202-5 (Pubitemid 350273305)
42. Campbell EG, Weissman JS, Ehringhaus S, et al. 2007. Institutional academic-industry relationships. JAMA 298(15):1779-86 (Pubitemid 47598446)
43. Freshwater DM, Freshwater MF. 2011. Failure by deans of academic medical centers to disclose outside income. Arch. Intern. Med. 171(6):586-87
44. Dana J. 2009. How psychological research can inform policies for dealing with conflicts of interest in medicine. In Institute of Medicine Conflict of Interest in Medical Research, Education, and Practice, pp. D1-14. Washington, DC: Natl. Acad. Press
45. Stossel TP. 2005. Regulating academic-industrial research relationships-solving problems or stifling progress? N. Engl. J. Med. 353(10):1060-65 (Pubitemid 41262343)
46. Angell M. 2004. The Truth about the Drug Companies: How They Deceive Us and What to Do About It. New York: Random House
47. Brennan TA, Rothman DJ, Blank L, et al. 2006. Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. JAMA 295(4):429-33 (Pubitemid 43144979)
48. Agrawal S, Saluja I, Kaczorowski J. 2004. Aprospective before-and-after trial of an educational intervention about pharmaceutical marketing. Acad. Med. 79(11):1046-50 (Pubitemid 40228243)
49. Schneider J, Arora V, Kasza K, et al. 2006. Residents' perceptions over time of pharmaceutical industry interactions and gifts and the effect of an educational intervention. Acad. Med. 81(7):595-602 (Pubitemid 44270780)
50. Wilkes MS, Hoffman JR. 2001. An innovative approach to educating medical students about pharmaceutical promotion. Acad. Med. 76(12):1271-77 (Pubitemid 34094068)
51. Ehringhaus S, Korn D. 2004. U. S. medical school policies on individual financial conflicts of interest: results of an AAMC survey. https://www. aamc. org/download/75296/data/coiresults2003
52. Cooper RJ, Gupta M, Wilkes MS, et al. 2006. Conflict of interest disclosure policies and practices in peer-reviewed biomedical journals. J. Gen. Intern. Med. 21(12):1248-52 (Pubitemid 44665332)
53. ACCM E. 2007. The ACCME standards for commercial support. http://www. accme. org/
54. Schroter S, Morris J, Chaudhry S, et al. 2004. Does the type of competing interest statement affect readers' perceptions of the credibility of research? Randomised trial. BMJ 328(7442):742-43 (Pubitemid 38406427)
55. Edwards D, Ballantyne A. 2009. Patient awareness and concern regarding pharmaceutical manufacturer interactions with doctors. Intern. Med. J. 39(3):191-96
56. Weinfurt KP, Hall MA, Dinan MA, et al. 2008. Effects of disclosing financial interests on attitudes toward clinical research. J. Gen. Intern. Med. 23(6):860-66
57. Cain D, Loewenstein G, Moore D. 2005. The dirt on coming clean: the perverse effects of disclosing conflicts of interest. J. Legal Stud. 34:1-25 (Pubitemid 40549835)
58. Weinfurt KP, Seils DM, Tzeng JP, et al. 2008. Consistency of financial interest disclosures in the biomedical literature: the case of coronary stents. PLoS One 3(5):e2128
59. Harvard Medical School. 2010. Faculty of medicine committee on conflicts of interest and commitment: 2009-2010 review. http://hms. harvard. edu/public/coi/pdfs/2010-recommendations. pdf
60. Roseman M, Milette K, Bero LA, et al. 2011. Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments. JAMA 305(10):1008-17
61. Am. Med. Stud. Assoc. 2010. PharmFree Scorecard 2010. Reston, VA: AMS A. http://www. amsascorecard. org/
62. Pharm. Res. Manuf. Am. 2008. Code on interactions with healthcare professionals. http://www. phrma. org/sites/default/files/108/phrma-marketing- code-2008. pdf
63. Assoc. Am. Med. Coll. 2001. Protecting subjects, preserving trust, promoting progress: policy and guidelines for the oversight of individual financial interests in human subjects research. http://ccnmtl. columbia. edu/projects/rcr/rcr-conflicts/misc/Ref/AAMC-FirstReport
64. Appelbaum PS, Gold A. 2010. Psychiatrists' relationships with industry: the principal-agent problem. Harv. Rev. Psychiatry 18(5):255-65
65. Mendelson TB, Meltzer M, Campbell EG, et al. 2011. Conflicts of interest in cardiovascular clinical practice guidelines. Arch. Intern. Med. 171(6):577-84